Merus at ESMO on Zenocutuzumab (Zeno) in lung, Pancreatic Cancer

  Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced two abstracts were selected for presentation at the European Society for Medical Oncology Congress (ESMO) 2023.

The presentations will highlight updated interim clinical data for the targeted bispecific antibody, zenocutuzumab (Zeno), with an abstract and oral presentation concerning NRG1 fusion positive (NRG1+) non-small cell lung cancer (NSCLC) and an abstract presentation concerning NRG1+ pancreatic ductal adenocarcinoma (PDAC). The abstracts will be presented at the ESMO Congress 2023 taking place in Madrid, Spain October 20-24, 2023.

Merus is currently enrolling patients into the phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancer.

Title: Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)
Speaker: Alison Schram
Mini Oral 1315MO
Lecture Time 9:35-9:40 CEST
Saturday, October 21

Title: Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Poster Session 1618P
Sunday, October 22

The full abstracts will be published online via the ESMO website at 00:05 CEST on Monday, October 16. They will be available concurrently on the Merus website.

https://www.marketscreener.com/quote/stock/MERUS-N-V-27548017/news/Merus-Announces-Two-Clinical-Abstracts-on-Zenocutuzumab-Zeno-in-NRG1-fusion-NRG1-non-small-cell-44452945/